GOLDMAN SACHS GROUP INC - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 217 filers reported holding REVANCE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$2,399,398
-10.3%
933,618
+71.8%
0.00%
Q1 2024$2,673,769
-61.2%
543,449
-30.6%
0.00%
-100.0%
Q4 2023$6,888,090
-47.5%
783,628
-31.5%
0.00%
-66.7%
Q3 2023$13,129,066
-70.2%
1,144,644
-34.2%
0.00%
-66.7%
Q2 2023$44,062,230
+24.6%
1,740,902
+58.5%
0.01%
+12.5%
Q1 2023$35,375,921
+58.1%
1,098,290
-9.4%
0.01%
+60.0%
Q4 2022$22,370,936
+72594.3%
1,211,860
+6.3%
0.01%
-37.5%
Q3 2022$30,774
+168.6%
1,139,808
+37.5%
0.01%
+166.7%
Q2 2022$11,456
-99.9%
828,925
+26.3%
0.00%0.0%
Q1 2022$12,803,000
-2.7%
656,556
-18.5%
0.00%0.0%
Q4 2021$13,155,000
-20.6%
806,032
+35.5%
0.00%
-25.0%
Q3 2021$16,568,000
+20.1%
594,700
+27.8%
0.00%
+33.3%
Q2 2021$13,796,000
+10.2%
465,436
+4.0%
0.00%0.0%
Q1 2021$12,514,000
+9.3%
447,715
+10.8%
0.00%0.0%
Q4 2020$11,452,000
+0.6%
404,126
-10.7%
0.00%0.0%
Q3 2020$11,379,000
-16.9%
452,616
-19.3%
0.00%
-25.0%
Q2 2020$13,696,000
+26.5%
560,875
-23.3%
0.00%0.0%
Q1 2020$10,827,000
+518.3%
731,534
+577.9%
0.00%
Q4 2019$1,751,000
+80.3%
107,908
+44.4%
0.00%
Q3 2019$971,000
+39.5%
74,715
+39.2%
0.00%
Q2 2019$696,000
-60.7%
53,685
-52.3%
0.00%
-100.0%
Q1 2019$1,772,000
+123.2%
112,458
+185.0%
0.00%
Q4 2018$794,000
-61.7%
39,462
-52.7%
0.00%
-100.0%
Q3 2018$2,072,000
-44.6%
83,370
-38.8%
0.00%0.0%
Q2 2018$3,739,000
+105.7%
136,242
+130.8%
0.00%
Q1 2018$1,818,000
+91.6%
59,021
+122.3%
0.00%
Q4 2017$949,000
-81.4%
26,546
-85.6%
0.00%
-100.0%
Q3 2017$5,093,000
+7.4%
184,880
+2.9%
0.00%0.0%
Q2 2017$4,743,000
-58.4%
179,657
-67.3%
0.00%
-66.7%
Q1 2017$11,412,000
+35.4%
548,650
+34.7%
0.00%
+50.0%
Q4 2016$8,430,000
+22.2%
407,250
-4.3%
0.00%0.0%
Q3 2016$6,900,000
+19.3%
425,625
+0.1%
0.00%0.0%
Q2 2016$5,782,000
+10.4%
425,179
+41.7%
0.00%0.0%
Q1 2016$5,239,000
-51.4%
300,056
-5.0%
0.00%
-33.3%
Q4 2015$10,788,000
-5.0%
315,826
-17.2%
0.00%
-25.0%
Q3 2015$11,353,000
+14.5%
381,485
+23.1%
0.00%
+33.3%
Q2 2015$9,912,000
+14.9%
309,938
-25.5%
0.00%0.0%
Q1 2015$8,623,000
+26.4%
415,965
+3.3%
0.00%
+50.0%
Q4 2014$6,823,000
-17.0%
402,755
-5.3%
0.00%
-33.3%
Q3 2014$8,224,000
-45.0%
425,445
-3.2%
0.00%
-40.0%
Q2 2014$14,950,000
+95.2%
439,702
+80.9%
0.01%
+66.7%
Q1 2014$7,658,000243,1030.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 4,592,047$121,230,00021.92%
Rhenman & Partners Asset Management AB 220,000$5,808,0000.83%
ArrowMark Colorado Holdings LLC 2,045,862$54,011,0000.67%
Vivo Capital, LLC 77,373$2,043,0000.52%
Ghost Tree Capital, LLC 89,295$2,357,0000.49%
ESSEX INVESTMENT MANAGEMENT CO LLC 124,932$3,298,0000.47%
Polar Capital LLP 1,296,371$34,220,0000.46%
SUFFOLK CAPITAL MANAGEMENT LLC 70,095$1,851,0000.24%
EAM Investors, LLC 33,897$895,0000.15%
PointState Capital LP 438,200$11,568,0000.13%
View complete list of REVANCE THERAPEUTICS INC shareholders